GlassScriptPhysician profile
Kimberlie Keyser Yadon
NPI 1316718968
$909.07
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $909.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $112.14 | 2024 | Sunosi, Auvelity |
| Corcept Therapeutics | $103.53 | 2024 | Korlym |
| Abbvie INC. | $89.93 | 2024 | |
| Corium, LLC | $70.22 | 2024 | Azstarys |
| Novo Nordisk INC | $66.28 | 2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $59.12 | 2024 | Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $57.34 | 2024 | Farxiga |
| Avadel Cns Pharmaceuticals, LLC | $55.35 | 2024 | Lumryz |
| Aimmune Therapeutics, INC. | $41.28 | 2024 | |
| Jazz Pharmaceuticals INC. | $32.97 | 2024 | |
| Exact Sciences Corporation | $31.74 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $28.52 | 2024 | |
| Vanda Pharmaceuticals INC. | $28.51 | 2024 | Fanapt |
| Merck Sharp & Dohme LLC | $26.92 | 2024 | Verquvo |
| Otsuka America Pharmaceutical, INC. | $23.84 | 2024 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.23 | 2024 | Trulance, Xifaxan |
| Optinose US, INC. | $20.78 | 2024 | |
| Tris Pharma INC | $20.15 | 2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $18.22 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberlie Yadon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.